Literature DB >> 6319107

New and experimental therapeutic roles for naloxone and related opioid antagonists.

L F McNicholas, W R Martin.   

Abstract

Naloxone and related opioid antagonists have been shown to have therapeutic utility in a variety of conditions. The effects of opioid antagonists in either physiological or pathological processes are most clearly seen when there is excessive occupancy of opioid receptors, as in opiate overdose. Opioid antagonists are also able to reverse several types of cardiovascular shock, conditions in which endogenous opioids appear to be mobilised, resulting in increased opioid receptor occupation. There are also more controversial circumstances in which excessive occupation of opioid receptors may assume pathological significance, such as hypercapnia. Opioid antagonists could be useful in such a situation by re-sensitising the respiratory centres to carbon dioxide. There is some evidence that opioid antagonists may benefit some schizophrenic and manic-depressive patients, suggesting that an endogenous opioid ligand might cause disturbances in mental functioning. The diversity and complexity of opioid mechanisms in the central nervous system suggest that more specific opioid antagonists could be more selective in altering physiological or pathological functioning.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6319107     DOI: 10.2165/00003495-198427010-00004

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  106 in total

1.  Autoradiographic studies concerning the supraspinal site of the antinociceptive action of morphine when inhibiting the hindleg flexor reflex in rabbits.

Authors:  H Teschemacher; P Schubert; A Herz
Journal:  Neuropharmacology       Date:  1973-02       Impact factor: 5.250

2.  Naloxone in schizophrenia: negative result.

Authors:  J Lipinski; R Meyer; C Kornetsky; B M Cohen
Journal:  Lancet       Date:  1979-06-16       Impact factor: 79.321

3.  Locomotor activity and antinociception after putative mu, kappa and sigma opioid receptor agonists in the rat: influence of dopaminergic agonists and antagonists.

Authors:  E T Iwamoto
Journal:  J Pharmacol Exp Ther       Date:  1981-05       Impact factor: 4.030

4.  Intravenous naloxone administration in schizophrenia and affective illness.

Authors:  G C Davis; W E Bunney; E G DeFraites; J E Kleinman; D P van Kammen; R M Post; R J Wyatt
Journal:  Science       Date:  1977-07-01       Impact factor: 47.728

5.  Increased CSF levels of endorphines in chronic psychosis.

Authors:  L Terenius; A Wahlström; L Lindström; E Widerlöv
Journal:  Neurosci Lett       Date:  1976-10       Impact factor: 3.046

6.  Antagonism of general anesthesia by naloxone in the rat.

Authors:  A D Finck; S H Ngai; B A Berkowitz
Journal:  Anesthesiology       Date:  1977-04       Impact factor: 7.892

7.  Characterization of the respiratory activity of (D-Ala2)methionine-enkephalinamide.

Authors:  R H Zobrist; H W Allerton; G E Isom
Journal:  Eur J Pharmacol       Date:  1981-03-12       Impact factor: 4.432

8.  Naloxone treatment of endotoxin shock: stereospecificity of physiologic and pharmacologic effects in the rat.

Authors:  A I Faden; J W Holaday
Journal:  J Pharmacol Exp Ther       Date:  1980-03       Impact factor: 4.030

9.  Vagal bradycardia produced by microinjections of morphine-like drugs into the nucleus ambiguus in anaesthetized dogs.

Authors:  M Laubie; H Schmitt; M Vincent
Journal:  Eur J Pharmacol       Date:  1979-11-16       Impact factor: 4.432

10.  Effects of naloxone and fentanyl in acutely decerebrated dogs.

Authors:  K M Wu; W R Martin
Journal:  Life Sci       Date:  1982-07-12       Impact factor: 5.037

View more
  9 in total

1.  Potentiation of disruptive effects of dextromethorphan by naloxone on fixed-interval performance in rats.

Authors:  T Taşkin
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

2.  Phylogenetic studies in Papaver section Oxytona: cytogenetics of the species and interspecific hybrids.

Authors:  J Milo; A Levy; G Ladizinsky; D Palevitch
Journal:  Theor Appl Genet       Date:  1986-07       Impact factor: 5.699

Review 3.  The role of naltrexone in the management of drug abuse.

Authors:  H M Ginzburg; M G MacDonald
Journal:  Med Toxicol       Date:  1987 Mar-Apr

4.  Effect of clonidine on beta-endorphin, ACTH and cortisol secretion in essential hypertension and obesity.

Authors:  J Słowinska-Srzednicka; S Zgliczynski; P Soszynski; J Puciłowska; M Wierzbicki; W Jeske
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

5.  Effect of in vivo administration of naloxone on ATP-ase's enzyme systems of synaptic plasma membranes from rat cerebral cortex.

Authors:  A Gorini; A Rancati; A D'Angelo; E Devecchi; R F Villa
Journal:  Neurochem Res       Date:  2000-06       Impact factor: 3.996

Review 6.  Naltrexone. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of opioid dependence.

Authors:  J P Gonzalez; R N Brogden
Journal:  Drugs       Date:  1988-03       Impact factor: 9.546

7.  Inheritance of morphological and chemical characters in interspecific hybrids between Papaver bracteatum and Papaver pseudo-orientale.

Authors:  A Levy; J Milo
Journal:  Theor Appl Genet       Date:  1991-04       Impact factor: 5.699

Review 8.  Clinical pharmacological and therapeutic considerations in general intensive care. A review.

Authors:  M L Farina; M Bonati; G Iapichino; A Pesenti; F Procaccio; L Boselli; M Langer; A Graziina; G Tognoni
Journal:  Drugs       Date:  1987-12       Impact factor: 9.546

9.  Nitric oxide in the hippocampal cortical area interacts with naloxone in inducing pain.

Authors:  Zahra K Hafeshjani; Manizheh Karami; Masoomeh Biglarnia
Journal:  Indian J Pharmacol       Date:  2012 Jul-Aug       Impact factor: 1.200

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.